Clinical Trial Update: Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease [Phase 2]

View source ↗

Summary

This Phase 2 randomized trial evaluated safety, tolerability, and pilot efficacy of AN-1792 in Alzheimer's disease, but the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AN-1792

Snippet

Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED